Simcere to collaborate with Sun Yat-Sen University Cancer Center to research and develop anti-cancer drugs

Simcere Pharmaceutical Group (NYSE: SCR) ("Simcere" or the "Company"), a leading manufacturer and supplier of branded generic and innovative pharmaceuticals in China, today announced a strategic partnership with Sun Yat-Sen University Cancer Center.

Located in Guangzhou, Sun Yat-Sen University Cancer Center is one of China's renowned cancer research institutions, prominent in pre-clinical and clinical oncology research. The Sun Yat-Sen University Cancer Center was established to research anti-cancer treatments with a specific focus on developing major innovative drugs.

Through the strategic partnership, Simcere Pharmaceutical Group and Sun Yat-Sen University Cancer Center will cooperate on researching and developing innovative anti-cancer drugs, as well as conducting a joint training program to develop personnel in advanced R&D.

"We are delighted to enter into a strategic partnership with Sun Yat-Sen University Cancer Center, one of China's outstanding cancer research institutions," said Mr. Jinsheng Ren, Chairman and Chief Executive Officer of Simcere Pharmaceutical Group. "I am confident that this cooperation will enhance Simcere's R&D capabilities and contribute to the future development of innovative cancer drugs in China."